| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -320,622 | -246,507 | -212,830 | -307,291 |
| Depreciation and amortization | 2,947 | 7,497 | 3,064 | 5,835 |
| Stock-based compensation expense | 37,964 | 35,997 | 35,306 | 67,542 |
| Amortization of operating lease right-of-use assets | 2,907 | 2,303 | 2,133 | 4,028 |
| Net accretion of discounts on investments | 3,112 | 2,764 | 2,264 | 9,406 |
| Unrealized foreign exchange loss (gain) | -2,201 | 1,655 | 789 | 32,324 |
| Prepaid expenses and other current assets | 8,743 | 9,549 | -915 | 8,166 |
| Operating lease right-of-use assets | 0 | 34,796 | 0 | 17,575 |
| Other assets | 16,876 | 11,539 | 11,316 | 17,031 |
| Operating lease liabilities | -1,285 | 33,137 | -1,401 | 14,635 |
| Accounts payable | -269 | 21,667 | 17,877 | -19,638 |
| Accrued compensation | -15,018 | 6,226 | 5,948 | -9,872 |
| Accrued contract manufacturing expenses | 54,852 | -32,145 | 19,987 | 43,217 |
| Accrued expenses | -15,571 | 7,296 | 65 | -1,394 |
| Net cash used in operating activities | -280,625 | -224,832 | -143,305 | -287,440 |
| Purchases of property and equipment | 2,107 | 2,654 | 3,824 | 7,235 |
| Purchases of manufacturing facility build-out and equipment construction-in-progress | 12,687 | 5,767 | 8,222 | 29,271 |
| Purchases of investments | 584,129 | 292,649 | 255,315 | 663,535 |
| Maturities of investments | 340,631 | 347,972 | 350,200 | 832,964 |
| Sales of investments | 24,882 | 68,223 | 38,331 | 68,136 |
| Net cash provided by (used in) investing activities | -233,410 | 115,125 | 121,170 | 201,059 |
| Proceeds from issuance of common stock and pre-funded warrants from follow-on offerings, net of issuance costs | NaN | 0 | NaN | NaN |
| Proceeds from issuance of common stock under at-the-market offering, net of issuance costs | NaN | 0 | 0 | 0 |
| Proceeds from issuance of shares through employee equity incentive plans | 9,032 | 3,415 | 306 | 9,284 |
| Proceeds from issuance of common stock from follow-on offering, net of issuance costs | 601,846 | NaN | 0 | 0 |
| Taxes paid related to the net share settlement of equity awards | 9,295 | 1,007 | 3,977 | 6,007 |
| Net cash provided by financing activities | 601,583 | 2,408 | -3,671 | 3,277 |
| Effect of exchange rate changes on cash and cash equivalents | -664 | 176 | 291 | 1,972 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 86,884 | -107,123 | -25,515 | -81,132 |
| Cash, cash equivalents and restricted cash, beginning of period | 175,425 | 282,548 | 389,195 | NaN |
| Cash, cash equivalents and restricted cash, end of period | 262,309 | 175,425 | 282,548 | NaN |
Vaxcyte, Inc. (PCVX)
Vaxcyte, Inc. (PCVX)